Analytical Data
-
Gene name
DRB5
- Application
-
Alternative Names
dsRNA-binding protein 5 Short name: AtDRB5
-
Species
Arabidopsis thaliana
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8GY79
-
Expression Region
1-393aa
-
Molecular Weight
45.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of DRB5 recombinant protein is situated at the intersection of immunology and molecular biology, focusing on understanding the role of Major Histocompatibility Complex (MHC) class II molecules in the immune response. DRB5, a gene within the MHC class II region, is essential for presenting antigens to CD4+ T cells, a critical step in initiating adaptive immunity. Variants of DRB5 have been associated with susceptibility or resistance to various autoimmune diseases and infections, making it a vital target for research. Recombinant protein technology allows for the production of DRB5 in a controlled environment, enabling the investigation of its structural and functional properties. Analyzing DRB5 recombinant protein aids in elucidating its role in antigen presentation, identifying potential epitopes for vaccine development, and exploring therapeutic strategies for diseases associated with MHC class II polymorphisms. As such, research on DRB5 not only contributes to fundamental immunological knowledge but also has potential implications for developing novel treatments and preventive measures against autoimmune and infectious diseases.
